Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Investor Presentation (July 2024)
22 slides from Little Green Pharma's investor presentation, July 2024
Slide 1: The most trusted medicinal cannabis brand
ASX:LGP JULY 2024 The most trusted medicinal cannabis brand
Slide 2: Disclaimer
Disclaimer Disclaimer Not financial product advice This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) (“LGP”) and its This document does not constitute financial product advice or take into account your investment objectives, taxation activities current as
Slide 3: About LGP
ABOUT LGP About LGP • Vertically integrated medicinal cannabis and psychedelics group operating across the entire value chain • Production facilities in Australia and Denmark (EU) giving control over supply and access to key European markets • One of the most trusted cannabis suppliers in Australia
Slide 4: Meet the Team
MEET THE TEAM Meet the Team Board of Directors Non-Executive Chair Non-Executive Director Non-Executive Director Executive Director Executive Director Michael Lynch-Bell Dr Neale Fong Beatriz Vicen Fleta Solomon Angus Caithness Executive Team CEO Executive Director Executive Director General Counsel
Slide 5: The most Trusted Brand
TRUSTED BRAND The most Trusted Brand WINNER Accolades: International Health 2023 – Healthcare & Pharmaceutical Award; Little Green Pharma WINNER – most pioneering medicinal cannabis company in Australia 2023 – The Cannabiz Awards; WINNER –Best Patient-Focused Initiative - LGP's Compassionate Access
Slide 6: Growth Strategy
GROWTH STRATEGY Growth Strategy LGP’s strategy recognises: • a significant pool of non-cannabis patients with chronic conditions including pain, insomnia and anxiety seeking alternative treatment options • illicit medical cannabis markets already well-established, with patients incentivised to move
Slide 7: Market Evolution
MARKET EVOLUTION Market Evolution Australia • ~12% (2.77 million) of Australia’s population already consumes cannabis1 of which ~1 million are prescribed patients2 • 17% of the Australian population has anxiety disorder, increasing to 32% for persons between 16 – 25 years3 • 14.8% of the Australian
Slide 8: Market Evolution
MARKET EVOLUTION Market Evolution Global cannabis markets are evolving rapidly as changing trends and demographics continually drive demand for new brands and formulations Australia • Australia is one of the fasting growing cannabis markets globally, with over one million prescribed patients accessi
Slide 9: Market Evolution
MARKET EVOLUTION Market Evolution International • International regulatory developments including partial legalisation in Germany, the anticipated Federal down-scheduling in the US, and new French medicinal cannabis framework are anticipated to drive significant demand • LGP very well positioned to
Slide 10: Global Footprint
GLOBAL FOOTPRINT Global Footprint • LGP has supply arrangements for medicinal cannabis products into 11 countries • LGP has grown its supply footprint since 2019, beginning in Australia and progressing through Europe including Germany, the UK, France, Italy and Poland LGP LGP markets markets TAM Mar
Slide 11: Key European Markets
KEY EUROPEAN MARKETS Key European Markets France • Key EU market favouring LGP given large population, LGP’s trial supply, first- mover advantage, existing in-country partnerships, and high regulatory barriers to entry • Recently shipped first commercial shipment with further high-value order shippi
Slide 12: Key European Markets
KEY EUROPEAN MARKETS Key European Markets Poland • Important market for LGP given large population and high regulatory barriers to entry • LGP one of only a few suppliers with Marketing Authorisation in territory Italy • Large population and high regulatory barriers to entry with limited access thro
Slide 13: Production Assets
PRODUCTION ASSETS Production Assets Owns and operates two medicinal Manufacturing facility in Perth cannabis production sites in (WA) for production of psilocybin Denmark (EU) and Busselton (WA) Denmark (EU) • One of the largest medicinal cannabis production facilities in Europe • Built by Canopy Gr
Slide 14: Production Assets
PRODUCTION ASSETS Production Assets Busselton (WA) • Indoor Craft facility • Capacity to produce >2.0 tonnes p.a. of biomass for Craft flower • Expanding current flower portfolio including genetics exchanges with Danish facility 14
Slide 15: Products
PRODUCTS Products Implementing House of Brands Developing two further Sales of over 1 tonne of strategy with 26 products in formulation ranges and CherryCo products market across three formulations three further brands for since December 2023 under multiple brands release in coming quarters 2018 201
Slide 16: Research and Development
RESEARCH & DEVELOPMENT Research and Development • In February 2021, LGP launched the QUEST Initiative, one of the largest longitudinal studies into medicinal cannabis globally • In 2023, peer-reviewed findings from the first 3-months of the QUEST Initiative were published in open access journal PLOS
Slide 17: Reset Mind Sciences update
RESET MIND SCIENCES update Incorporated in May 2021 to leverage LGP’s Sch 9 license and botanical GMP expertise giving Reset a two-year head start on TGA down-scheduling of psychedelics in 2023 Today, Reset is at the forefront of the psychedelics industry in Australia. Its four pillars are: 1. PSYCH
Slide 18: FY2024 Financials
FY2024 FINANCIALS FY2024 Financials For year ending 31 March 2024 REVENUE ($m) OPERATING CASH FLOW ($m) ADJUSTED EBITDA [1] ($m) 29% 101% 56% FY24 25.6 FY24 0.1 FY24 (3.3) FY23 19.9 (6.9) FY23 FY23 (7.5) CASH IN BANK [2] ($m) BORROWINGS ($m) NET TANGIBLE ASSETS ($m) 60% 70% 6% FY24 5.0 FY24 (3.5) FY
Slide 19: Operating Cashflows
CASHFLOWS Operating Cashflows • Achieved operating cashflow breakeven in FY2024 • Strong increase in receipts from customers while operating costs have remained consistent following • One of small number of Australian cannabis acquisition of its Danish facility companies to achieve operating cashflo
Slide 20: Corporate Overview
CORPORATE OVERVIEW Corporate Overview Capital Structure Shareholder Structure Current Share Price1 $0.10 Shares Outstanding1 ~302 million Options and Performance Rights on Issue2 ~16.9 million 22% 29% Market Capitalisation (undiluted) ~$30.2 million Cash Reserves (31 March 2024) ~$5.0 million 9% 18%
Slide 21: Value Proposition
VALUE PROPOSITION Value Proposition 1.Strong financial position • Positive operating cashflow in FY2024, a rare achievement in the Australian cannabis industry • Net tangible assets of $73 million compared to $30 million market cap • Very low debt ($3.5 million) compared to most ASX listed peers • $
Slide 22: A world of difference
A world of difference investor.littlegreenpharma.com
Little Green Pharma — Investor Presentation (July 2024) on 6ix